Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Language
Publication DateClinical Gastroenterology and Hepatology, ISSN 1542-3565, 2017, Volume 15, Issue 5, pp. 720 - 727.e1
Background and Aims Bile acids (BAs) are passively absorbed to a different extent along the mammalian colon, so that levels are lower in the feces than in...
Gastroenterology and Hepatology | CDCA | Lithocholate | Clinical Study | Intestine | ILEAL RESECTION | RABBIT COLON | RECEPTOR | SERUM | CHENODEOXYCHOLATE | TANDEM MASS-SPECTROMETRY | 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE | TGR5 | SECRETION | GASTROENTEROLOGY & HEPATOLOGY | MOTILITY | Cross-Sectional Studies | Colon - pathology | Humans | Middle Aged | Male | Minnesota | Diarrhea - pathology | Gastrointestinal Transit | Feces - chemistry | Irritable Bowel Syndrome - pathology | Adult | Female | Bile Acids and Salts - analysis | Lipids - analysis | Diarrhea | Care and treatment | Continuing medical education | Epidemiology | Irritable bowel syndrome | Deoxycholic acid | Medicine, Experimental | Medical research | clinical study | intestine | lithocholate
Gastroenterology and Hepatology | CDCA | Lithocholate | Clinical Study | Intestine | ILEAL RESECTION | RABBIT COLON | RECEPTOR | SERUM | CHENODEOXYCHOLATE | TANDEM MASS-SPECTROMETRY | 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE | TGR5 | SECRETION | GASTROENTEROLOGY & HEPATOLOGY | MOTILITY | Cross-Sectional Studies | Colon - pathology | Humans | Middle Aged | Male | Minnesota | Diarrhea - pathology | Gastrointestinal Transit | Feces - chemistry | Irritable Bowel Syndrome - pathology | Adult | Female | Bile Acids and Salts - analysis | Lipids - analysis | Diarrhea | Care and treatment | Continuing medical education | Epidemiology | Irritable bowel syndrome | Deoxycholic acid | Medicine, Experimental | Medical research | clinical study | intestine | lithocholate
Journal Article
Details 
Digital rights
Loading RightsAlimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2018, Volume 48, Issue 9, pp. 1034 - 1035
Linked Content This article is linked to Damsgaard et al and Walters papers. To view these articles visit https://doi.org/10.1111/apt.14533 and...
GASTROENTEROLOGY & HEPATOLOGY | PHARMACOLOGY & PHARMACY | MALABSORPTION | Diarrhea | Retrospective Studies | Bile Acids and Salts | Taurocholic Acid - analogs & derivatives | Humans | Chenodeoxycholic Acid - analogs & derivatives | Deoxycholic acid | Acids | Bile
GASTROENTEROLOGY & HEPATOLOGY | PHARMACOLOGY & PHARMACY | MALABSORPTION | Diarrhea | Retrospective Studies | Bile Acids and Salts | Taurocholic Acid - analogs & derivatives | Humans | Chenodeoxycholic Acid - analogs & derivatives | Deoxycholic acid | Acids | Bile
Journal Article
Details
Digital rights
Loading RightsJournal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 6, pp. 1398 - 1404
Graphical abstract
Gastroenterology and Hepatology | 3-hydroxy-3-methylglutaryl-CoA reductase | Stearoyl-CoA desaturase | Non-alcoholic fatty liver disease | Lipogenesis | FGF19 | 3-hydroxy-3-methylglutaryl- CoA reductase | FXR | NONALCOHOLIC STEATOHEPATITIS | AGONISTS | NUCLEAR RECEPTOR | CHOLESTEROL-METABOLISM | TRANSPORT | FEEDBACK-REGULATION | LIVER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Ursodeoxycholic Acid - administration & dosage | Oleic Acid - metabolism | Bile Acids and Salts - biosynthesis | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Intra-Abdominal Fat - metabolism | Obesity, Morbid - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Ursodeoxycholic Acid - pharmacology | Stearoyl-CoA Desaturase - biosynthesis | Liver - drug effects | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Lipid Metabolism - drug effects | Intra-Abdominal Fat - drug effects | Obesity, Morbid - metabolism | Physiological aspects | Obesity | Ursodiol | Deoxycholic acid | Index Medicus | BAs, bile acids | nCEH, neutral cholesterol ester hydrolase | ApoB, apolipoprotein B | LDLR, low density lipoprotein receptor | FGF19, fibroblast growth factor 19 | VLDL, very low density lipoproteins | ABC, ATP-binding cassette | TGs, triglycerides | NAFLD, non-alcoholic fatty liver disease | OA, oleic acid | C4, 7α-hydroxy-4-cholesten-3-one | SHP, small heterodimer partner | SREBP1c, sterol regulatory element-binding protein-1c | CA, cholic acid | PA, palmitic acid | FATP1, fatty acid transport protein 1 | UDCA, ursodeoxycholic acid | FAs, fatty acides | HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase | vWAT, visceral white adipose tissue | SCD, stearoyl-Coa desaturase | CYP7A1, cholesterol 7α-hydroxylase | NASH, non-alcoholic steatohepatitis | FXR, farnesoid X receptor | CDCA, chenodeoxycholic acid | MA, myristic acid | FASN, fatty acid synthase | MTTP, microsomal triglyceride transfer protein | SA, stearic acid | NONALCOHOLIC | FATTY LIVER-DISEASE | Gastroenterology & Hepatology | Endokrinologi och diabetes | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | COA DESATURASE | Endocrinology and Diabetes
Gastroenterology and Hepatology | 3-hydroxy-3-methylglutaryl-CoA reductase | Stearoyl-CoA desaturase | Non-alcoholic fatty liver disease | Lipogenesis | FGF19 | 3-hydroxy-3-methylglutaryl- CoA reductase | FXR | NONALCOHOLIC STEATOHEPATITIS | AGONISTS | NUCLEAR RECEPTOR | CHOLESTEROL-METABOLISM | TRANSPORT | FEEDBACK-REGULATION | LIVER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Ursodeoxycholic Acid - administration & dosage | Oleic Acid - metabolism | Bile Acids and Salts - biosynthesis | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Intra-Abdominal Fat - metabolism | Obesity, Morbid - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Ursodeoxycholic Acid - pharmacology | Stearoyl-CoA Desaturase - biosynthesis | Liver - drug effects | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Lipid Metabolism - drug effects | Intra-Abdominal Fat - drug effects | Obesity, Morbid - metabolism | Physiological aspects | Obesity | Ursodiol | Deoxycholic acid | Index Medicus | BAs, bile acids | nCEH, neutral cholesterol ester hydrolase | ApoB, apolipoprotein B | LDLR, low density lipoprotein receptor | FGF19, fibroblast growth factor 19 | VLDL, very low density lipoproteins | ABC, ATP-binding cassette | TGs, triglycerides | NAFLD, non-alcoholic fatty liver disease | OA, oleic acid | C4, 7α-hydroxy-4-cholesten-3-one | SHP, small heterodimer partner | SREBP1c, sterol regulatory element-binding protein-1c | CA, cholic acid | PA, palmitic acid | FATP1, fatty acid transport protein 1 | UDCA, ursodeoxycholic acid | FAs, fatty acides | HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase | vWAT, visceral white adipose tissue | SCD, stearoyl-Coa desaturase | CYP7A1, cholesterol 7α-hydroxylase | NASH, non-alcoholic steatohepatitis | FXR, farnesoid X receptor | CDCA, chenodeoxycholic acid | MA, myristic acid | FASN, fatty acid synthase | MTTP, microsomal triglyceride transfer protein | SA, stearic acid | NONALCOHOLIC | FATTY LIVER-DISEASE | Gastroenterology & Hepatology | Endokrinologi och diabetes | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | COA DESATURASE | Endocrinology and Diabetes
Journal Article
Details
Digital rights
Loading RightsJournal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 1, pp. 155 - 168
Summary Bile acid (BA) transporters are critical for maintenance of the enterohepatic BA circulation where BAs exert their multiple physiological functions...
Gastroenterology and Hepatology | Gallstones | Liver cancer | Bile acids | Fatty liver disease | Cholestasis | Liver regeneration | RAT-LIVER | SALT EXPORT PUMP | GROWTH-FACTOR 19 | ORGANIC ANION TRANSPORTERS | 90-PERCENT PARTIAL-HEPATECTOMY | URSODEOXYCHOLIC ACID | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | GASTROENTEROLOGY & HEPATOLOGY | PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS | FAMILIAL INTRAHEPATIC CHOLESTASIS | Animals | Carrier Proteins - metabolism | Cholestasis - metabolism | Membrane Glycoproteins - metabolism | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Liver Diseases - metabolism | Liver Regeneration - physiology | Receptors, Cytoplasmic and Nuclear - metabolism | Drug resistance in microorganisms | Corticosteroids | Glucagon | Calcifediol | Ursodiol | Deoxycholic acid | Epidermal growth factor | Vitamin D | Physiological aspects | Fibroblast growth factors | Alfacalcidol | IBABP (FABP6, ILBP), intestinal bile acid-binding protein, fatty acid-binding protein 6 | PFIC, progressive familial intrahepatic cholestasis | TNFα, tumor necrosis factor α | 3 (human) | SRC2, p160 steroid receptor coactivator | NAFLD, non-alcoholic fatty liver disease | BA, bile acid | bile acid receptor | 8, cholesterol efflux pump, ATP-binding cassette, subfamily G, member 5 | UDCA, ursodeoxycholic acid | LRH-1 (NR5A2), liver receptor homolog-1 | LCA, lithocholic acid | LXRα (NR1H3), liver X receptor alpha | PPARγ (NR1C3), peroxisome proliferator-activated receptor gamma | OSTαβ, organic solute transporter alpha | ABCG5 | AMPK, AMP activated protein kinase | NASH, non-alcoholic steatohepatitis | SHP (NR0B2), short heterodimer partner | OATP1A2 (SLCO1A2, OATP1, OATP-A, SLC21A3), solute carrier organic anion transporter family, member 1A2 | EGFR, epidermal growth factor receptor | IL6, interleukin 6 | TGR5, G protein-coupled bile acid receptor | PH, partial hepatectomy | AE2, anion exchanger 2 | PSC, primary sclerosing cholangitis | OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1 | RARα (NR1B1), retinoic acid receptor alpha | GLP-1, glucagon like peptide 1 | VDR (NR1I1), vitamin D receptor. Please note that for the convenience of better readability and clarity, abbreviations for transporters and nuclear receptors were capitalized throughout this article when symbols were identical for human and rodents | MRP2 (ABCC2), multidrug resistance-associated protein 2, ATP-binding cassette, subfamily C, member 2 | NTCP (SLC10A1), sodium | CAR (NR1I3), constitutive androstane receptor | taurocholate cotransporting polypeptide, solute carrier family 10, member 1 | PPARα (NR1C1), peroxisome proliferator-activated receptor alpha | Review | GR (NR3C1), glucocorticoid receptor | Bile acids, Cholestasis, Fatty liver disease, Gallstones, Liver regeneration, Liver cancer | 19, fibroblast growth factor 15 | Mdr2 | ICP, intrahepatic cholestasis of pregnancy | BRIC, benign recurrent intrahepatic cholestasis | OATP1B3 (SLCO1B3, OATP8, SLC21A8), solute carrier organic anion transporter family, member 1B3 | MRP3 (ABCC3), multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3 | beta | MDR1 (ABCB1), p-glycoprotein, ATP-binding cassette, subfamily B, member 1 | norUDCA, norursodeoxycholic acid | 6-ECDCA, 6-ethylchenodeoxycholic acid | FXR (NR1H4), farnesoid X receptor | BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2 | HNF4α (NR2A1), hepatocyte nuclear factor 4 alpha | PBC, primary biliary cirrhosis | MDR3 (ABCB4), multidrug resistance protein 2 (rodents) | HNF1α, hepatocyte nuclear factor 1 alpha | NR, nuclear receptor | FGF15 | RXRα (NR2B1), retinoid X receptor alpha | PXR (NR1I2), pregnane X receptor | BSEP (ABCB11), bile salt export pump | HCC, hepatocellular carcinoma | MRP4 (ABCC4), multidrug resistance-associated protein 4, ATP-binding cassette, subfamily C, member 4 | TPN, total parenteral nutrition
Gastroenterology and Hepatology | Gallstones | Liver cancer | Bile acids | Fatty liver disease | Cholestasis | Liver regeneration | RAT-LIVER | SALT EXPORT PUMP | GROWTH-FACTOR 19 | ORGANIC ANION TRANSPORTERS | 90-PERCENT PARTIAL-HEPATECTOMY | URSODEOXYCHOLIC ACID | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | GASTROENTEROLOGY & HEPATOLOGY | PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS | FAMILIAL INTRAHEPATIC CHOLESTASIS | Animals | Carrier Proteins - metabolism | Cholestasis - metabolism | Membrane Glycoproteins - metabolism | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Liver Diseases - metabolism | Liver Regeneration - physiology | Receptors, Cytoplasmic and Nuclear - metabolism | Drug resistance in microorganisms | Corticosteroids | Glucagon | Calcifediol | Ursodiol | Deoxycholic acid | Epidermal growth factor | Vitamin D | Physiological aspects | Fibroblast growth factors | Alfacalcidol | IBABP (FABP6, ILBP), intestinal bile acid-binding protein, fatty acid-binding protein 6 | PFIC, progressive familial intrahepatic cholestasis | TNFα, tumor necrosis factor α | 3 (human) | SRC2, p160 steroid receptor coactivator | NAFLD, non-alcoholic fatty liver disease | BA, bile acid | bile acid receptor | 8, cholesterol efflux pump, ATP-binding cassette, subfamily G, member 5 | UDCA, ursodeoxycholic acid | LRH-1 (NR5A2), liver receptor homolog-1 | LCA, lithocholic acid | LXRα (NR1H3), liver X receptor alpha | PPARγ (NR1C3), peroxisome proliferator-activated receptor gamma | OSTαβ, organic solute transporter alpha | ABCG5 | AMPK, AMP activated protein kinase | NASH, non-alcoholic steatohepatitis | SHP (NR0B2), short heterodimer partner | OATP1A2 (SLCO1A2, OATP1, OATP-A, SLC21A3), solute carrier organic anion transporter family, member 1A2 | EGFR, epidermal growth factor receptor | IL6, interleukin 6 | TGR5, G protein-coupled bile acid receptor | PH, partial hepatectomy | AE2, anion exchanger 2 | PSC, primary sclerosing cholangitis | OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1 | RARα (NR1B1), retinoic acid receptor alpha | GLP-1, glucagon like peptide 1 | VDR (NR1I1), vitamin D receptor. Please note that for the convenience of better readability and clarity, abbreviations for transporters and nuclear receptors were capitalized throughout this article when symbols were identical for human and rodents | MRP2 (ABCC2), multidrug resistance-associated protein 2, ATP-binding cassette, subfamily C, member 2 | NTCP (SLC10A1), sodium | CAR (NR1I3), constitutive androstane receptor | taurocholate cotransporting polypeptide, solute carrier family 10, member 1 | PPARα (NR1C1), peroxisome proliferator-activated receptor alpha | Review | GR (NR3C1), glucocorticoid receptor | Bile acids, Cholestasis, Fatty liver disease, Gallstones, Liver regeneration, Liver cancer | 19, fibroblast growth factor 15 | Mdr2 | ICP, intrahepatic cholestasis of pregnancy | BRIC, benign recurrent intrahepatic cholestasis | OATP1B3 (SLCO1B3, OATP8, SLC21A8), solute carrier organic anion transporter family, member 1B3 | MRP3 (ABCC3), multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3 | beta | MDR1 (ABCB1), p-glycoprotein, ATP-binding cassette, subfamily B, member 1 | norUDCA, norursodeoxycholic acid | 6-ECDCA, 6-ethylchenodeoxycholic acid | FXR (NR1H4), farnesoid X receptor | BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2 | HNF4α (NR2A1), hepatocyte nuclear factor 4 alpha | PBC, primary biliary cirrhosis | MDR3 (ABCB4), multidrug resistance protein 2 (rodents) | HNF1α, hepatocyte nuclear factor 1 alpha | NR, nuclear receptor | FGF15 | RXRα (NR2B1), retinoid X receptor alpha | PXR (NR1I2), pregnane X receptor | BSEP (ABCB11), bile salt export pump | HCC, hepatocellular carcinoma | MRP4 (ABCC4), multidrug resistance-associated protein 4, ATP-binding cassette, subfamily C, member 4 | TPN, total parenteral nutrition
Journal Article
Details
Digital rights
Loading RightsFASEB Journal, ISSN 0892-6638, 09/2017, Volume 31, Issue 9, pp. 3848 - 3857
Bile acids and epithelial-derived human beta-defensins (H beta Ds) are known to be important factors in the regulation of colonic mucosal barrier function and...
Innate immunity | UDCA | HbD | Epithelium | HUMAN BETA-DEFENSINS | CANCER CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | GUT MICROBIOTA | CELL BIOLOGY | ADAPTIVE IMMUNITY | INTESTINAL EPITHELIUM | IN-VITRO | INFLAMMATORY-BOWEL-DISEASE | innate immunity | EXPERIMENTAL COLITIS | BIOLOGY | GENE-EXPRESSION | epithelium | NF-KAPPA-B | Colon - cytology | Cell Line | Ursodeoxycholic Acid - administration & dosage | beta-Defensins - genetics | Receptors, G-Protein-Coupled - metabolism | Tissue Culture Techniques | Humans | RNA, Messenger - genetics | NF-kappa B - metabolism | Epithelial Cells | beta-Defensins - secretion | RNA, Messenger - metabolism | Mice, Knockout | Dose-Response Relationship, Drug | Intestinal Mucosa - cytology | Ursodeoxycholic Acid - pharmacology | Animals | Deoxycholic Acid - pharmacology | NF-kappa B - genetics | Deoxycholic Acid - administration & dosage | Mice | Receptors, G-Protein-Coupled - genetics | beta-Defensins - metabolism | NF-κB protein | Phosphorylation | G protein-coupled receptors | Bile acids | Epithelial cells | Secretion | Mucosa | Ursodeoxycholic acid | Deoxycholic acid | Acids | Defensins | Intestine | Animal tissues | Colon | Inhibition | Bile | Life Sciences
Innate immunity | UDCA | HbD | Epithelium | HUMAN BETA-DEFENSINS | CANCER CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | GUT MICROBIOTA | CELL BIOLOGY | ADAPTIVE IMMUNITY | INTESTINAL EPITHELIUM | IN-VITRO | INFLAMMATORY-BOWEL-DISEASE | innate immunity | EXPERIMENTAL COLITIS | BIOLOGY | GENE-EXPRESSION | epithelium | NF-KAPPA-B | Colon - cytology | Cell Line | Ursodeoxycholic Acid - administration & dosage | beta-Defensins - genetics | Receptors, G-Protein-Coupled - metabolism | Tissue Culture Techniques | Humans | RNA, Messenger - genetics | NF-kappa B - metabolism | Epithelial Cells | beta-Defensins - secretion | RNA, Messenger - metabolism | Mice, Knockout | Dose-Response Relationship, Drug | Intestinal Mucosa - cytology | Ursodeoxycholic Acid - pharmacology | Animals | Deoxycholic Acid - pharmacology | NF-kappa B - genetics | Deoxycholic Acid - administration & dosage | Mice | Receptors, G-Protein-Coupled - genetics | beta-Defensins - metabolism | NF-κB protein | Phosphorylation | G protein-coupled receptors | Bile acids | Epithelial cells | Secretion | Mucosa | Ursodeoxycholic acid | Deoxycholic acid | Acids | Defensins | Intestine | Animal tissues | Colon | Inhibition | Bile | Life Sciences
Journal Article
Details
Digital rights
Loading RightsJournal of Lipid Research, ISSN 0022-2275, 11/2010, Volume 51, Issue 11, pp. 3230 - 3242
An improved ultra performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method was established for the simultaneous analysis of various bile...
Bile acid-synthetic enzymes | Ultra performance liquid chromatography-tandem mass spectrometry | Gender difference | PERFUSED RAT-LIVER | DETOXIFICATION | NUCLEAR RECEPTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE-LIVER | gender difference | LITHOCHOLIC ACID | SULFOTRANSFERASE | DEOXYCHOLIC-ACID | BIOTRANSFORMATION | METABOLISM | ultra performance liquid chromatography-tandem mass spectrometry | bile acid-synthetic enzymes | CHENODEOXYCHOLIC ACID | Reproducibility of Results | Bile Acids and Salts - pharmacology | Sulfates - metabolism | Liver - metabolism | Mice, Inbred C57BL | RNA, Messenger - genetics | Bile Acids and Salts - chemistry | Bile Acids and Salts - metabolism | Male | Chromatography, High Pressure Liquid | RNA, Messenger - metabolism | Gene Expression Regulation - drug effects | Tandem Mass Spectrometry | Animals | Liver - drug effects | Bile Acids and Salts - isolation & purification | Chenodeoxycholic Acid - metabolism | Sex Factors | Female | Mice | Dietary Supplements | Index Medicus
Bile acid-synthetic enzymes | Ultra performance liquid chromatography-tandem mass spectrometry | Gender difference | PERFUSED RAT-LIVER | DETOXIFICATION | NUCLEAR RECEPTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE-LIVER | gender difference | LITHOCHOLIC ACID | SULFOTRANSFERASE | DEOXYCHOLIC-ACID | BIOTRANSFORMATION | METABOLISM | ultra performance liquid chromatography-tandem mass spectrometry | bile acid-synthetic enzymes | CHENODEOXYCHOLIC ACID | Reproducibility of Results | Bile Acids and Salts - pharmacology | Sulfates - metabolism | Liver - metabolism | Mice, Inbred C57BL | RNA, Messenger - genetics | Bile Acids and Salts - chemistry | Bile Acids and Salts - metabolism | Male | Chromatography, High Pressure Liquid | RNA, Messenger - metabolism | Gene Expression Regulation - drug effects | Tandem Mass Spectrometry | Animals | Liver - drug effects | Bile Acids and Salts - isolation & purification | Chenodeoxycholic Acid - metabolism | Sex Factors | Female | Mice | Dietary Supplements | Index Medicus
Journal Article
Details
Digital rights
Loading RightsClinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 12, pp. 2085 - 2091.e1
Background & Aims We investigated the effects of the fatty acid–bile acid conjugate 3β-arachidyl-amido, 7α-12α-dihydroxy, 5β-cholan-24-oic acid (Aramchol;...
Gastroenterology and Hepatology | Cholic Acid | Clinical Trial | NASH | Lipid | Steatosis | VITAMIN-E | ENDOTHELIAL DYSFUNCTION | MAGNETIC-RESONANCE-SPECTROSCOPY | PIOGLITAZONE | INSULIN-RESISTANCE | INFLAMMATION | BARIATRIC SURGERY | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | HEPATIC STEATOSIS | Liver - pathology | Double-Blind Method | Fats - analysis | Magnetic Resonance Spectroscopy | Humans | Middle Aged | Male | Treatment Outcome | Non-alcoholic Fatty Liver Disease - drug therapy | Pregnancy | Young Adult | Placenta | Biopsy | Adolescent | Gastrointestinal Agents - therapeutic use | Cholic Acids - adverse effects | Adult | Female | Aged | Gastrointestinal Agents - adverse effects | Israel | Cholic Acids - therapeutic use | Care and treatment | Fatty liver | Fatty acids | Deoxycholic acid
Gastroenterology and Hepatology | Cholic Acid | Clinical Trial | NASH | Lipid | Steatosis | VITAMIN-E | ENDOTHELIAL DYSFUNCTION | MAGNETIC-RESONANCE-SPECTROSCOPY | PIOGLITAZONE | INSULIN-RESISTANCE | INFLAMMATION | BARIATRIC SURGERY | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | HEPATIC STEATOSIS | Liver - pathology | Double-Blind Method | Fats - analysis | Magnetic Resonance Spectroscopy | Humans | Middle Aged | Male | Treatment Outcome | Non-alcoholic Fatty Liver Disease - drug therapy | Pregnancy | Young Adult | Placenta | Biopsy | Adolescent | Gastrointestinal Agents - therapeutic use | Cholic Acids - adverse effects | Adult | Female | Aged | Gastrointestinal Agents - adverse effects | Israel | Cholic Acids - therapeutic use | Care and treatment | Fatty liver | Fatty acids | Deoxycholic acid
Journal Article
Details
Digital rights
Loading RightsMolecular Metabolism, ISSN 2212-8778, 04/2019, Volume 22, pp. 96 - 109
The gut microbiota is an important influencing factor of metabolic health. Although dietary interventions with probiotics, prebiotics, and synbiotics can be...
Gut microbiota | Obesity | Dietary intervention | High-fat diet | Synbiotics | PHYSIOLOGY | HIGH-FAT-DIET | PROBIOTICS | OLIGOFRUCTOSE | GENOME SEQUENCE | OVERWEIGHT | PREBIOTICS | ENDOCRINOLOGY & METABOLISM | SP-NOV | INTERVENTION | BILE-ACIDS | Index Medicus
Gut microbiota | Obesity | Dietary intervention | High-fat diet | Synbiotics | PHYSIOLOGY | HIGH-FAT-DIET | PROBIOTICS | OLIGOFRUCTOSE | GENOME SEQUENCE | OVERWEIGHT | PREBIOTICS | ENDOCRINOLOGY & METABOLISM | SP-NOV | INTERVENTION | BILE-ACIDS | Index Medicus
Journal Article
Details
Digital rights
Loading RightsAlimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2018, Volume 48, Issue 9, pp. 1032 - 1034
Linked Content This article is linked to Damsgaard et al papers. To view these articles visit https://doi.org/10.1111/apt.14533 and...
GASTROENTEROLOGY & HEPATOLOGY | PHARMACOLOGY & PHARMACY | Diarrhea | Retrospective Studies | Bile Acids and Salts | Taurocholic Acid - analogs & derivatives | Humans | Chenodeoxycholic Acid - analogs & derivatives | Deoxycholic acid | Acids | Bile
GASTROENTEROLOGY & HEPATOLOGY | PHARMACOLOGY & PHARMACY | Diarrhea | Retrospective Studies | Bile Acids and Salts | Taurocholic Acid - analogs & derivatives | Humans | Chenodeoxycholic Acid - analogs & derivatives | Deoxycholic acid | Acids | Bile
Journal Article
Details
Digital rights
Loading RightsDermatologic Surgery, ISSN 1076-0512, 04/2017, Volume 43, Issue 4, pp. 609 - 610
Journal Article
Details
Digital rights
Loading RightsApplied and Environmental Microbiology, ISSN 0099-2240, 05/2018, Volume 84, Issue 10
Bile acids are important cholesterol-derived nutrient signaling hormones, synthesized in the liver, that act as detergents to solubilize dietary lipids. Bile...
12α-hydroxysteroid dehydrogenase | Oxo-bile acids | Clostridium hiranonis | Bile acid 7α-dehydroxylation | Cholic acid | Clostridium hylemonae | Human gut bacteria | Clostridium scindens | Deoxycholic acid | cholic acid | 12 alpha-hydroxysteroid dehydrogenase | EUBACTERIUM-LENTUM | 7-ALPHA-HYDROXYSTEROID DEHYDROGENASE | MICROBIOLOGY | deoxycholic acid | VPI 12708 | FUNCTIONAL-CHARACTERIZATION | oxo-bile acids | bile acid 7 alpha-dehydroxylation | DEOXYCHOLIC-ACID | SALT BIOTRANSFORMATIONS | BACTEROIDES-FRAGILIS | URSODEOXYCHOLIC ACID | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | human gut bacteria | SP STRAIN VPI-12708 | PARTIAL-PURIFICATION | Index Medicus
12α-hydroxysteroid dehydrogenase | Oxo-bile acids | Clostridium hiranonis | Bile acid 7α-dehydroxylation | Cholic acid | Clostridium hylemonae | Human gut bacteria | Clostridium scindens | Deoxycholic acid | cholic acid | 12 alpha-hydroxysteroid dehydrogenase | EUBACTERIUM-LENTUM | 7-ALPHA-HYDROXYSTEROID DEHYDROGENASE | MICROBIOLOGY | deoxycholic acid | VPI 12708 | FUNCTIONAL-CHARACTERIZATION | oxo-bile acids | bile acid 7 alpha-dehydroxylation | DEOXYCHOLIC-ACID | SALT BIOTRANSFORMATIONS | BACTEROIDES-FRAGILIS | URSODEOXYCHOLIC ACID | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | human gut bacteria | SP STRAIN VPI-12708 | PARTIAL-PURIFICATION | Index Medicus
Journal Article
Details
Digital rights
Loading RightsBritish Journal of Pharmacology, ISSN 0007-1188, 06/2013, Volume 169, Issue 3, pp. 671 - 684
Background and Purpose Nutrient sensing in the gut is believed to be accomplished through activation of GPCRs expressed on enteroendocrine cells. In...
glucagon‐like peptide 1 | cyclic adenosine monophosphate | glucose tolerance | bile acid | incretin | GLP‐1 secretion | glucagon-like peptide 1 | GLP-1 secretion | CELLS | PEPTIDE-YY | ACTIVATION | FOOD-INTAKE | TGR5 | INHIBITION | COLESEVELAM | GLUCOSE | PHARMACOLOGY & PHARMACY | EXPRESSION | INCRETIN SECRETION | Cricetulus | Isonipecotic Acids - pharmacology | Oximes - pharmacokinetics | Receptors, G-Protein-Coupled - metabolism | Hypoglycemic Agents - metabolism | Humans | Macaca fascicularis | Oximes - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Receptors, G-Protein-Coupled - agonists | Peptide YY - secretion | Enteroendocrine Cells - secretion | Glucagon-Like Peptide 1 - secretion | Piperidines - pharmacology | Mice, Mutant Strains | Oximes - metabolism | Piperidines - pharmacokinetics | Enteroendocrine Cells - metabolism | Gastrointestinal Agents - pharmacokinetics | CHO Cells | Hypoglycemic Agents - therapeutic use | Recombinant Proteins - metabolism | Cell Line | Hypoglycemic Agents - pharmacokinetics | Isonipecotic Acids - pharmacokinetics | Metabolic Detoxication, Phase II | Piperidines - metabolism | Recombinant Proteins - chemistry | Mice, Transgenic | Isonipecotic Acids - therapeutic use | Hypoglycemic Agents - pharmacology | Isonipecotic Acids - metabolism | Gastrointestinal Agents - pharmacology | Animals | Piperidines - therapeutic use | Gastrointestinal Agents - therapeutic use | Oximes - pharmacology | Mice | Receptors, G-Protein-Coupled - genetics | Diabetes Mellitus, Type 2 - drug therapy | Enteroendocrine Cells - drug effects | Taurine - metabolism | Gastrointestinal Agents - metabolism | Glucose metabolism | Taurine | Glucagon | Monkeys | Glucose | G proteins | Dextrose | Deoxycholic acid | Rodents | Bioavailability | Bile | Research Papers
glucagon‐like peptide 1 | cyclic adenosine monophosphate | glucose tolerance | bile acid | incretin | GLP‐1 secretion | glucagon-like peptide 1 | GLP-1 secretion | CELLS | PEPTIDE-YY | ACTIVATION | FOOD-INTAKE | TGR5 | INHIBITION | COLESEVELAM | GLUCOSE | PHARMACOLOGY & PHARMACY | EXPRESSION | INCRETIN SECRETION | Cricetulus | Isonipecotic Acids - pharmacology | Oximes - pharmacokinetics | Receptors, G-Protein-Coupled - metabolism | Hypoglycemic Agents - metabolism | Humans | Macaca fascicularis | Oximes - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Receptors, G-Protein-Coupled - agonists | Peptide YY - secretion | Enteroendocrine Cells - secretion | Glucagon-Like Peptide 1 - secretion | Piperidines - pharmacology | Mice, Mutant Strains | Oximes - metabolism | Piperidines - pharmacokinetics | Enteroendocrine Cells - metabolism | Gastrointestinal Agents - pharmacokinetics | CHO Cells | Hypoglycemic Agents - therapeutic use | Recombinant Proteins - metabolism | Cell Line | Hypoglycemic Agents - pharmacokinetics | Isonipecotic Acids - pharmacokinetics | Metabolic Detoxication, Phase II | Piperidines - metabolism | Recombinant Proteins - chemistry | Mice, Transgenic | Isonipecotic Acids - therapeutic use | Hypoglycemic Agents - pharmacology | Isonipecotic Acids - metabolism | Gastrointestinal Agents - pharmacology | Animals | Piperidines - therapeutic use | Gastrointestinal Agents - therapeutic use | Oximes - pharmacology | Mice | Receptors, G-Protein-Coupled - genetics | Diabetes Mellitus, Type 2 - drug therapy | Enteroendocrine Cells - drug effects | Taurine - metabolism | Gastrointestinal Agents - metabolism | Glucose metabolism | Taurine | Glucagon | Monkeys | Glucose | G proteins | Dextrose | Deoxycholic acid | Rodents | Bioavailability | Bile | Research Papers
Journal Article
Details
Digital rights
Loading Rights